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Abstract
Background: CD133+ stem cells represent a promising subpopulation for innovative cell-based therapies in
cardiovascular regeneration. Several clinical trials have shown remarkable beneficial effects following their
intramyocardial transplantation. Yet, the purification of CD133+ stem cells is typically performed in centralized clean
room facilities using semi-automatic manufacturing processes based on magnetic cell sorting (MACS®). However,
this requires time-consuming and cost-intensive logistics.
Methods: CD133+ stem cells were purified from patient-derived sternal bone marrow using the recently developed
automatic CliniMACS Prodigy® BM-133 System (Prodigy). The entire manufacturing process, as well as the subsequent
quality control of the final cell product (CP), were realized on-site and in compliance with EU guidelines for Good
Manufacturing Practice. The biological activity of automatically isolated CD133+ cells was evaluated and compared to
manually isolated CD133+ cells via functional assays as well as immunofluorescence microscopy. In addition, the
regenerative potential of purified stem cells was assessed 3 weeks after transplantation in immunodeficient mice which
had been subjected to experimental myocardial infarction.
Results: We established for the first time an on-site manufacturing procedure for stem CPs intended for the treatment
of ischemic heart diseases using an automatized system. On average, 0.88 × 106 viable CD133+ cells with a mean log10
depletion of 3.23 ± 0.19 of non-target cells were isolated. Furthermore, we demonstrated that these automatically
isolated cells bear proliferation and differentiation capacities comparable to manually isolated cells in vitro. Moreover,
the automatically generated CP shows equal cardiac regeneration potential in vivo.
Conclusions: Our results indicate that the Prodigy is a powerful system for automatic manufacturing of a CD133+ CP
within few hours. Compared to conventional manufacturing processes, future clinical application of this system offers
multiple benefits including stable CP quality and on-site purification under reduced clean room requirements. This will
allow saving of time, reduced logistics and diminished costs.
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Background
Adult stem cells remain of particular interest as thera-
peutic agents for cardiac regeneration in ischemic heart
disease [1–4]. Recently, several clinical trials showed an
increased left ventricular ejection fraction (LVEF) and an
improved regional perfusion following intramyocardial
application of cluster of differentiation (CD) 133+ stem
cells [5–9]. These adult cells represent a subset of CD34+
progenitors and are easily accessible from patient-derived
bone marrow (BM) posing little ethical conflicts [10–12].
The regeneration potential of these cells is mainly based
on their direct contribution to neovascularization and on
their secretion of various paracrine factors activating pro-
angiogenic mechanisms [13–16].
According to the European Medicines Agency (EMA)
BM-derived CD133+ stem cells intended for the regener-
ation of human ischemic heart tissue are classified as an
advanced therapy medicinal product (ATMP) [17]. As a
prerequisite for their clinical application, they need to be
manufactured under standardized conditions and in
compliance with EU guidelines for Good Manufacturing
Practice (GMP) [18]. Yet, CD133+ stem cells for clinical
use are purified using manual or semi-automatic devices
based on the conventional magnetic cell sorting
(MACS®) technique. Such purification requires high-
level clean room facilities [19] and time-consuming lo-
gistics (Additional file 1: Figure S1a). Therefore, the de-
velopment of an automatic system is urgently needed to
guarantee stable product quality, to simplify the manu-
facturing procedure and to reduce the risk of contamin-
ation (Additional file 1: Figure S1b).
In this study, we evaluated the recently developed CE-
marked CliniMACS Prodigy® BM-133 System (Prodigy)
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany)
in order to assess its suitability for the automatic manu-
facturing of a CD133+ cell product (CP) [20–22]. The
entire manufacturing process, the examination of cell
number and viability of the final CP as well as the deple-
tion of non-target cells were part of the validation
process, which was performed in compliance with EU
guidelines for GMP. Furthermore, preclinical data were
collected to compare proliferation and differentiation
capacities of manually and automatically isolated CD133+
stem cells in accordance to Organisation for Economic
Co-operation and Development (OECD) principles for
Good Laboratory Practice (GLP) [23]. In addition, the effi-
cacy of purified stem cells was assessed in immunodefi-
cient mice 3 weeks after induction of myocardial
infarction (MI).
Methods
Equipment and facility characteristics
The manufacturing process of the automatically gener-
ated CP was established at the Department of Cardiac
Surgery (Rostock University Medical Center, Germany).
The data were collected during the GMP inspection
process, which led to the certification of GMP in com-
pliance with EU guidelines (license DE_MV_01_-
MIA_2016_0001/310.0003.02), quality control (QC) and
media fill validation were performed by the Institute for
Clinical Chemistry and Laboratory Medicine (ILAB,
Rostock University Medical Center) and the Institute for
Medical Microbiology, Virology and Hygiene (IMIKRO,
Rostock University Medical Center), which are accre-
dited for compliance with clinical laboratory quality
standards (ILAB: DIN EN ISO 15189, DIN EN ISO
22870, license D-ML-13193_02_00; IMIKRO: DIN EN
ISO 15189, DIN EN ISO/IEC 17025). Data of in vitro
colony-forming unit (CFU) assays were collected during
the GLP evaluation process, which led to the statement
of GLP compliance of the Reference and Translation
Center for Cardiac Stem Cell Therapy (RTC). Therefore
these experiments are closely aligned to the OECD prin-
ciples for GLP [23] and the German Chemicals Act
(ChemG §19a).
BM aspiration
Sternal BM was aspirated from informed donors who
gave their written consent to use their samples for re-
search according to the Declaration of Helsinki. The eth-
ics committee of Rostock University Medical Center has
approved the presented study (registered as number A
2010 23) in 2010 (renewal in 2015). BM samples were
obtained by sternal aspiration from patients undergoing
coronary artery bypass graft (CABG) surgery at Rostock
University Medical Center. Samples from six donors
were used for automatic isolation and samples from an-
other six donors for manual isolation. The mean volume
of BM subjected to the automatic separation was 59.17
± 2.6 ml (Additional file 2: Table S1a) with a mean donor
age of 69 ± 4 years (including 83% of male donors)
whereas for the manual isolation 56.5 ± 1.71 ml BM
(Additional file 3: Table S2) with a mean donor age of
72 ± 2 years (including 100% of male donors) was used.
Anticoagulation was achieved by heparinization with
250 IU/ml sodium heparin (Ratiopharm GmbH, Ulm,
Germany).
Manual cell isolation
Mononuclear cells from BM samples were isolated by
density gradient centrifugation on Pancoll (PAN-Biotech
GmbH, Aidenbach, Germany). CD133+ cells were
enriched by positive magnetic selection using the
MACS® cell separation system (Miltenyi Biotec). Label-
ing with direct anti-CD133 magnetic beads (Miltenyi
Biotec) was performed as recommended by the manu-
facturer’s manual instructions. Total numbers of living
cells were determined using trypan blue dye (0.4%,
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Sigma-Aldrich, Taufkirchen, Germany) and Neubauer
hemocytometer (Carl Roth GmbH + Co. KG, Karlsruhe,
Germany). Viability and frequency of CD133+ stem
cells of BM and manually generated CPs were verified
using BD LSRII flow cytometer and fluorescence-
activated cell sorting (FACS) Diva software version 6.1.2
(Becton Dickinson, Heidelberg, Germany) (see below).
Automatic cell isolation
All components of the Prodigy (consisting of the Clini-
MACS Prodigy® device, the CliniMACS Prodigy® Tubing
Set (TS) 100, the CliniMACS® CD133 Reagent and the
CliniMACS® Buffer (phosphate-buffered saline (PBS)/
ethylenediaminetetraacetic acid (EDTA)) are CE-marked
medical devices and were provided by Miltenyi Biotec.
Medical products sodium chloride (NaCl, 0.9%) and hu-
man serum albumin (HSA, 20%) were obtained from
Fresenius Kabi (Bad Homburg, Germany) and CSL
Behring (Marburg, Germany), respectively.
By using the functionally closed Prodigy, CD133+ cells
from sternal BM were purified in a mostly automatic
procedure, which was performed by two operators under
standardized conditions in compliance with EU guide-
lines for GMP (Additional file 4: Figure S2). For the iso-
lation process, the BM-CD133 enrichment program was
selected on the device. After installation of the TS 100,
an integrity test was performed to control the leak-
tightness of the TS. Subsequently, BM was applied to the
system and after filtration an appropriate sample of non-
diluted BM was taken into the BM pouch. To ensure
automatic generation of plasma, BM aspirate was filled
up with a fixed volume of 70 ml PBS/EDTA buffer sup-
plemented with 20% HSA. Afterward, cell processing
was performed following the selected enrichment pro-
gram. Finally, the following fractions were obtained: CP
(eluted in 0.9% NaCl supplemented with 10% autologous
plasma), non-target cell bag (NTCB) and waste bag
(WB). Next, all fraction bags were welded off and
weighed with the consideration 1 g ≙ 1 ml. In an add-
itional non-automatic step, 0.5 ml samples from the BM
pouch and CP bag were taken for QC under aseptic con-
ditions (laminar air flow, LAF). Samples of remaining
fractions (NTCB, WB) were taken in some cases for fur-
ther investigation (product quality review (PQR)).
Prodigy media fill validation
In order to validate safety and reproducibility of the
automatic aseptic manufacturing process in compliance
with Ph. Eur. 5.1.1 as well as the relevant EU guidelines
for GMP, a media fill validation [24] was performed.
During this simulation BM, NaCl and CliniMACS®
CD133 Reagent were replaced with Casein peptone Soy-
bean flour peptone (CASO) Bouillon EP + USP medium
(Merck Millipore, Darmstadt, Germany). At the end of
the media fill process all manufactured samples (BM,
CP) were transported to IMIKRO and tested for micro-
bial growth according to Ph. Eur. 2.6.1/2.6.27 [24]. To
verify the potential microbial growth, samples were incu-
bated either at 35–37 °C under anaerobic or at 30–32 °C
under aerobic conditions for 14 days. Simultaneously,
the turbidity of the remaining NTCB and WB fractions
was observed every day.
Flow cytometric analysis of manually isolated cells
Frequency and viability of manually isolated CD133+
stem cells using a MACS® cell separation system were
analyzed directly after the isolation procedure by flow
cytometry. All utilized antibodies were mouse anti-
human and are listed in Additional file 5: Table S3.
Compensation was established using single-stained con-
trols and gating was performed with matched isotype/
fluorescence minus one (FMO) controls. The Boolean
gating strategy for CD133+ cells was arranged on the
basis of the International Society of Hematotherapy and
Graft Engineering (ISHAGE) guidelines for CD34+ cell
analysis [25] as described previously by our group [26].
Cell samples were suspended in MACS® buffer. FcR
blocking reagent (Miltenyi Biotec) was added in order to
reduce unspecific bindings. Subsequently, cells were in-
cubated with antibodies for 10 min in the dark at 4 °C.
To distinguish viable from dead cells, 7-amino-
actinomycin (7-AAD) staining solution (BD) was used.
After staining, red blood cell lysis buffer (eBioscience,
Frankfurt am Main, Germany) was added and samples
were incubated for 10 min on ice. Flow cytometry meas-
urement was realized within the next 1 h by a BD™ LSRII
flow cytometer. At least 1000 events were acquired within
the final gate (viable CD45+/CD34+/CD133+ cells). This
corresponds to the ISHAGE guidelines, which require a
minimum of 100 events to be recorded in the target cell
population. Analysis was performed using FACSDiva
software (BD).
QC and PQR of automatically generated fractions
After the automatic manufacturing process, BM, CP and
PQR samples (NTCB, WB) were transported under con-
trolled conditions (temperature: 24 °C; average time:
13 min) to ILAB and flow cytometric analysis were per-
formed in compliance with EU guidelines for GMP. Cells
were stained in duplicates with CD45-FITC/CD34-PE
reagent and 7-AAD viability dye using IVD-certified
Stem-Kit™ (Beckman Coulter (BC), Marseille, France)
and with CD133-APC antibody (clone 293C2, APC con-
jugate, Miltenyi Biotec) (Additional file 5: Table S3). For
each sample, a control staining with mouse isotype
IgG2a-APC instead of CD133-APC was prepared. For
calculation of cell numbers, 100 μl of a pre-mix of Stem
Count Fluorospheres (included in the Stem-Kit™) was
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added to each tube. The measurement was performed
using the Navios Flow Cytometer (BC) with scattergram
analysis based on ISHAGE guidelines [25]. For QC, the
CP was measured for 10 min in order to record at least
1000 events. A representative example of the gating
strategy is shown in Additional file 6: Figure S5. The de-
pletion of non-target cells [− logCP] according to Mohr
et al. [27] was calculated as follows:
− logCP ¼ − log10 ðviable CD45
þCP−viable CD133þCPÞ
viable CD45þBM−viable CD133þBMð Þ
For PQR, thrombocyte and erythrocyte numbers were
additionally analyzed using Sysmex XE-5000 (Sysmex
Deutschland GmbH, Norderstedt, Germany).
The IMIKRO further tested microbial growth in CP,
BM and PQR samples as described above (Prodigy
media fill validation). Moreover, microbiological moni-
toring (LAF and fingerprints of the operator) was per-
formed during the isolation process.
In order to evaluate the stability of the automatically
generated CP over time, the CP bag was stored at room
temperature (RT) for 2.5 h followed by 4 °C up to 24 h
after manufacturing process and samples were taken for
QC at the respective time points.
Samples used to investigate the biological activity of
the CP were taken 2.5 h after the manufacturing process,
since this represents a time span realistic for QC under
optimal conditions.
Acceptance criteria for the automatically generated
CD133+ CP
Parameters selected to evaluate the quality of the auto-
matically generated CD133+ CP using the Prodigy were
based on the PERFECT clinical trial (clinicaltrials.gov,
Identifier: NCT00950274). However, for ethical reasons
in this study BM from the sternum served as a starting
material while in the PERFECT clinical trial BM from
the iliac crest was used. Therefore, acceptance criteria
were correspondingly adapted. Briefly, a viability of
≥70%, a cellularity of 0.05 − 5 × 106 viable CD133+ cells
in 5 ml CP and depletion of non-target cells ≥2.5 log
were considered as suitable.
Expression of stemness-related proteins in the automatically
generated CP
The expression of additional stemness (CD117, CD184,
CD309) and maturation (CD14) markers in the CP was
analyzed by flow cytometry in a multicolor panel as de-
scribed previously by our group [26]. Data acquisition
was performed based on ISHAGE gating strategy used
for QC. All utilized antibodies were mouse anti-human
and are listed in Additional file 5: Table S3.
1 × 104 automatically enriched cells were suspended in
MACS® buffer and FcR blocking reagent. Following this,
cells were incubated with antibodies for 30 min in the
dark at 4 °C. To distinguish viable from dead cells,
LIVE/DEAD® Fixable Near-IR Dead Cell Stain Kit
(Molecular Probes, Eugene, OR, USA) was used. Flow
cytometry measurements were realized by BD™ LSRII
flow cytometer and analysis was performed using
FACSDiva software.
Detection of apoptotic and necrotic cells in the
automatically generated CP
In order to analyze the percentage of apoptotic and nec-
rotic cells in the CP over a storage time of 24 h, the
Annexin V Apoptosis Detection Kit (eBioscience) was
performed in accordance to the manufacturer’s instruc-
tions. Annexin V – APC and 7-AAD were used to dis-
tinguish between early-stage apoptotic (Annexin V+),
late-stage apoptotic (Annexin V+/7-AAD+), and necrotic
(7-AAD+) cells.
Hematopoietic colony-forming unit (CFU-H) assay
1 × 103 CD133+ cells were plated in duplicates on a 35-
mm dish in MethoCult H4434 Classic (Stemcell Tech-
nologies Inc., Vancouver, BC, Canada) 2.5 h after the
manufacturing process following the manufacturer’s in-
structions in accordance with the OECD principles for
GLP. After 14 days of incubation at 37 °C and 5% CO2,
formed colonies were scored as CFU-erythroid (CFU-E),
burst-forming unit-erythroid (BFU-E), CFU-granulocyte,
macrophage (CFU-GM) and CFU-granulocyte, erythro-
cyte, macrophage, megakaryocyte (CFU-GEMM).
Colony-forming unit endothelial cell (CFU-EC) assay
1 × 103 CD133+ cells were plated in triplicates on a 35-
mm dish in supplemented MethoCult SF H4236 (Stem-
cell Technologies Inc.) 2.5 h after the manufacturing
process as previously described [28] in accordance to
OECD principles for GLP. After 14 days of incubation at
37 °C and 5% CO2, adherent and non-adherent colonies
were counted.
Immunofluorescence staining of non-adherent cells from
CFU-EC assay
In order to confirm the endothelial phenotype of non-
adherent cells immunofluorescence staining was per-
formed. Therefore, non-adherent cells obtained from the
CFU-EC assay were collected after 29 days of incubation
by dissolving the supplemented MethoCult SF H4236
with 1 U/ml dispase (Stemcell Technologies Inc.). Cells
were counted by TC20™ Automated Cell Counter (Bio-
Rad Laboratories Inc., Hercules, CA, USA) and 1.5 × 105
were cultured for 3 additional days in Endothelial Cell
Growth Medium (EGM)-2 (Lonza Group Ltd., Basel,
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Switzerland) on fibronectin-coated coverslips (Human
Plasma Fibronectin from Merck Millipore, 10 μg/ml in
PBS).
For uptake analyses of acetylated low-density lipopro-
tein (acLDL), cells on coverslips were incubated with
10 μg/ml of Alexa Fluor 488-labeled acLDL antibody
(Thermo Fisher Scientific, Schwerte, Germany) for 1 h
at 37 °C. Subsequently, cells were fixed with 4% parafor-
maldehyde (PFA, Merck Millipore) and nuclei were
stained with Hoechst dye (1:1000, Sigma-Aldrich).
For immunostaining of von Willebrand factor (vWF)
cells were fixed with 4% PFA, permeabilized with 0.1%
Triton X-100 (Sigma-Aldrich) for 7 min at RT and
blocked with 1% bovine serum albumin (BSA, Sigma-
Aldrich) in PBS for 1 h at RT. Afterward, cells were
stained with rabbit polyclonal vWF primary antibody
(1:50, Santa Cruz Biotechnology Inc., Dallas, TX, USA)
overnight at 4 °C, goat anti-rabbit Alexa Fluor 488 sec-
ondary antibody (1:350, Thermo Fisher Scientific) for
3 h at 37 °C and counterstained with Hoechst dye
(1:1000, Sigma-Aldrich).
Finally, all coverslips were mounted on a microscope
slide using FluorSave™ (Merck Millipore) and pictures
were taken and analyzed using ELYRA PS.1 LSM 780
microscope and ZEN 2011 software (Carl Zeiss GmbH,
Jena, Germany). For acLDL uptake and vWF expression,
tiles scans of 850 μm x 850 μm were acquired using
the × 40 objective.
Experimental design of the animal model
The federal animal care committee of Landesamt für
Landwirtschaft, Lebensmittelsicherheit und Fischerei
Mecklenburg-Vorpommern (LALLF M-V, Germany) ap-
proved the study protocol (registered as number LALLF
M-V/TSD/7221.3-1.1-088/11). Severe combined immu-
nodeficient beige mice (SCID bg; strain CB17.Cg-
PrkdcscidLystbg-J/Crl) were purchased from Charles River
Laboratories (Sulzfeld, Germany). SCID bg mice (female,
22 ± 2 g) were randomly assigned to four groups: healthy
control group (SHAM), two MI groups with human
CD133+ stem cell treatment of the respective method
(MI133 manual, MI133 automatic) and untreated MI
control group (MIC).
Generation of reperfused MI and intramyocardial stem
cell implantation
Mice were anesthetized with pentobarbital (50 mg/kg,
intraperitoneal). After thoracotomy and preparation, the
left anterior descending coronary artery (LAD) was li-
gated. After 45 min each mouse received an intramyo-
cardial injection. For cell treatment 1 × 105 CD133+ stem
cells were suspended in 10 μl of MACS® buffer (PBS
(PAN-Biotech GmbH) supplemented with 0.5% BSA and
2 mM EDTA (Thermo Fisher Scientific)) and mixed with
an equal amount of BD Matrigel™ Matrix 2.5 h after the
manufacturing process. Both control groups underwent
the same approach without cells. Injections of 4 × 5 μl
were given along the border of the blanched myocar-
dium and ligation was removed. SHAM-operated mice
underwent identical surgical procedures without LAD
ligation.
Left ventricular catheterization
Three weeks after surgery, mice underwent pressure-
volume (PV) loop measurements according to the proto-
col of CardioDynamics BV (CD Leycom, Zoetermeer,
Netherlands). Data were collected with the Millar
Pressure-Volume System (consisting of the Ultra-
Miniature Pressure-Volume Catheter (model SPR-1030),
the Pressure Conductance Unit (model MPCU-200) and
the PowerLab data-acquisition hardware). Calibration of
pressure and volume was performed by equating the
minimal and maximal conductance with minimal
(0 mmHg) and maximal (100 mmHg) pressures as well
as minimal and maximal blood volumes received from
venous circulation. After inserting the catheter into the
carotid artery, retrograde access to the left ventricle (LV)
was achieved. PV loops were recorded under normal
conditions (baseline) followed by stress conditions medi-
ated by intravenous dobutamine administration (10 μg/
kg/min, Sigma-Aldrich). Volume signal was corrected by
measurement of wall conductance (parallel volume) via
hypertonic saline (5%) injection. Data were analyzed
with IOX Version 1.8.3.20 software (Emka Technologies,
Paris, France). After PV loop measurements blood
vessels were stained with 7.5 μg/ml of biotinylated
Lycopersicon esculentum (tomato) lectin (LINARIS,
Wertheim-Bettingen, Germany) by perfusion of the
venous circulation for 10 min. For euthanization hearts
were arrested in diastole with potassium chloride.
Organ harvesting
Each heart was removed, embedded in O.C.T.™ Com-
pound (Tissue-Tek®; Sakura Finetek, Zoeterwoude,
Netherlands) and snap-frozen in liquid nitrogen. For
histological and biomolecular investigations the infarct
area of heart tissue has been divided into four horizontal
levels from the apex to the base and within each sections
of 5 μm were cut.
Infarction size and fibrosis
Heart sections of four horizontal infarction levels (5 μm)
were stained with Sirius Red (Division Chroma, Muenster,
Germany) visualizing collagen deposition and Fast Green
FCF (Sigma-Aldrich) displaying uninjured muscle tissue.
To investigate the infarction size, two contiguous levels of
the heart, which represent the major infarction ratio, were
analyzed using computerized planimetry (Axio Vision
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LE Rel. 4.5 software; Carl Zeiss GmbH). To evaluate
fibrosis, the Sirius Red-positive regions of collagen de-
position in the infarction border zone (BZ) and remote
area (RA) were examined in five randomly chosen fields
(each per section; one section per level) using comput-
erized planimetry. Collagen deposition was expressed
as the ratio of collagen deposition to myocardial tissue
in percentage.
Determination of blood vessels
Tomato lectin perfusion of the hearts as described was
used for analysis of capillary density and angiogenesis.
Heart sections of two contiguous levels of the heart,
which represent the major infarction region, were fixed
with 4% PFA and immunostained with polyclonal goat
anti-biotin (Vector Laboratories; Burlingame, CA, USA)
primary antibody followed by anti-goat Alexa-Fluor 488
(Molecular Probes™/Thermo Fisher Scientific) conju-
gated secondary antibody and counterstained with 4′,6-
diamidino-2-phenylindole (DAPI; Sigma-Aldrich). The
sections were analyzed within the BZ, RA and infarcted
scar (IS) of the heart. Capillary density as well as neovas-
cularization were assessed by counting the number of
capillaries in five BZ, RA and IS randomly chosen fields
per section (one section per level). Results were
expressed as capillaries per high power field (HPF).
Statistical analysis
Statistical analysis was performed by Student’s t test with
SigmaPlot version 11.0 (Systat Software Inc., Chicago,
IL, USA). For analysis of possible correlation of normally
distributed variables, Pearson product-moment was
used. All values are presented as mean ± standard error
of the mean (SEM). P values ≤ 0.05 (*); ≤ 0.01 (**); and
≤ 0.001 (***) were considered as statistically significant.
Results
The Prodigy is a convenient tool to simplify and
standardize the manufacturing procedure of CPs
In this study, the whole manufacturing procedure of the
CD133+ CP (isolation, transport and QC) was estab-
lished on-site and in compliance with EU guidelines for
GMP using the Prodigy. Therefore, our hospital (Rostock
University Medical Center, Germany) has received for the
first time the certificate of GMP compliance of a manufac-
turer (license DE_MV_01_MIA_2016_0001/310.0003.02)
for this device.
Usage of the Prodigy enables purification of the CP
within approximately 4 h and requires only few interac-
tions of the operators (Additional file 4: Figure S2). This
will further diminish the risk of contamination and will
minimize inter-individual variability caused by the
manufacturing personnel, thereby resulting in higher
standardized product quality. Moreover, the entire on-
site manufacturing enables reduction of logistical efforts,
which in turn leads to a shorter hospitalization time of
patients and thereby also diminished costs.
The Prodigy is suitable for the automatic generation of a
CD133+ CP
Initially, we characterized the automatically generated
CD133+ CPs by evaluating QC-relevant parameters. The
CPs contained on average 0.52 × 106 ± 0.16 CD133+ stem
cells per 5 ml with a viability of 83.13 ± 3.9% and a mean
log10 depletion of 3.23 ± 0.19 was obtained, which is in
accordance to defined acceptance criteria (Table 1 and
Fig. 1c). Based on ISHAGE guidelines we calculated that
64.0 ± 8.8% of cells in the CP were CD45+/CD34+/CD133+
target cells (Additional file 2: Table S1a). Importantly, the
presence of thrombocytes, erythrocytes and lymphocytes
in the CP can be excluded based on results from full blood
counts (Sysmex analyses) and flow cytometric measure-
ments (Fig. 1d and e; Additional file 6: Figure S5h).
Reanalysis of the quality control data demonstrated
that the non-target cell fraction (36.4% of the CP)
consists of CD45+/CD34-/low/CD133− (28.8%) and
CD45+/CD34+/CD133− (7.6%) cells (regions J, Q and
I in Additional file 6: Figure S5b and e). Importantly,
the entire non-target population is characterized by a
hematopoietic phenotype due to its expression of the
CD45 marker. Moreover, CD45+/CD34low/CD133− (region
Q) and CD45+/CD34+/CD133− (region I) cells were found
to have similar size and granularity as the target cells
(>90%; regions S and P in the Additional file 7: Figure S6).
The analysis of various additional stem/progenitor cell
markers demonstrated that the non-target cell fraction
(CD45+/CD34−/CD133−) (region J) is characterized by the
Table 1 Acceptance criteria of the automatically generated cell
product (CP)
Validation no. No. of viable CD133+






1 1.0 97.92 3.86
2 0.28 77.17 2.82
3 0.57 71.42 2.60
4 0.19 87.13 3.46
5 0.12 77.66 3.49
6 0.97 87.53 3.17
Mean 0.52 83.14 3.23
SEM 0.16 3.90 0.19
Acceptance range 0.05–5 × 106 ≥70% ≥2.5 log
Number of viable CD133+ cells and cell viability of the automatically
generated CP were analyzed by flow cytometric analysis in accordance with
ISHAGE guidelines. Depletion of non-target cells was calculated as the negative
logarithm to base 10 of number of total CD133+ cells in CP divided by the
number of CD133+ cells in bone marrow. All data are presented
as mean ± SEM
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lowest expression of CD117 as well as the highest expres-
sion of CD184 (CXCR4) and CD309 (KDR, VEGFR2) in
comparison to all other non-target and target cell fractions
(Additional file 8: Table S4). Additionally, this fraction
showed also the highest expression of the maturation
marker CD14.
The stability analysis of the CP showed no significant
changes over the entire storage time in CD45+ and
CD133+/CD34+ cells per μl and cell viability (Fig. 2).
However, a trend to decrease was detectable for cells per
μl after 24 h. Moreover, no significant changes in the
percentage of apoptotic and necrotic cells for up to 24 h
post manufacturing were detected (Additional file 9:
Figure S7). In addition, all manufactured CPs were free
from microbial contamination as proven by microbio-
logical controls.
For characterization of all automatically generated
fractions mean volumes were determined by visual
control or by weighing. All volumes showed small SEMs
confirming the successful standardization of the manu-
facturing process (Additional file 2: Table S1a and b). In
comparison to CP the number of CD45+ cells per μl was
significantly higher in BM as well as NTCB, while it was
significantly lower in WB (Fig. 1a). Importantly, no target
cells were detected in WB (Fig. 1b; Additional file 2:
Table S1b). This indicates that most of the
hematopoietic cells were transferred from BM (starting
material) to the NTCB. The highest CD133+CD34+ cell
number per μl in CP demonstrates the efficient enrich-
ment of CD133+ stem cells by the Prodigy. The cell viabil-
ity of CP and NTCB (83.14 ± 3.90% and 90.65 ± 4.36%)
were comparable. BM showed slightly but significantly
higher cell viability (98.66 ± 0.36%) in comparison to CP
and NTCB, indicating the mild manufacturing condi-
tions. Additionally, the viability of CP did not correlate





Fig. 1 Characterization of automatically generated fractions. Cell product (CP), non-target cell bag (NTCB), waste bag (WB) and bone marrow (BM)
were analyzed in respect of their CD45+ cells/μl (a), CD133+CD34+ cells/μl (b) and viability of CD45+ cells (c) using flow cytometry measurement
in accordance with ISHAGE guidelines. Additionally, total numbers of thrombocytes (d) and erythrocytes (e) were assessed using a Sysmex device.
All data are presented as mean ± SEM. CP, BM (n = 6); NTCB, WB (n = 3). *p≤ 0.05; **p≤ 0.01; ***p ≤ 0.001 vs. CP
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correlation: r = 0.288; p = 0.580). The microbiological
monitoring of all validation runs resulted in <1 CFU,
showing that all processes were conducted under stan-
dardized aseptic conditions. Overall, the manufacturing
process lasted 3 h 27 min ± 12 min.
Manually and automatically isolated CD133+ cells bear
similar hematopoietic and endothelial differentiation
capacity
BM-derived CD133+ stem cells are known to bear
multipotent differentiation potential. In order to de-
tect the influence of the isolation process on their
hematopoietic and endothelial differentiation capacity,
CFU-H and CFU-EC assays were performed. The
comparison of manually and automatically isolated
cells showed neither a significant difference in the
amount of formed hematopoietic CFUs (CFU-E, BFU-
E, CFU-GEMM, CFU-GM) nor in the amount of
formed endothelial CFUs (adherent, non-adherent)
(Fig. 3). Immunofluorescence staining demonstrated
similar acLDL uptake (Additional file 10: Figure S3)
and vWF expression (Additional file 11: Figure S4) of
manually and automatically enriched CPs, confirming
their equal endothelial differentiation potential.
Manually and automatically isolated CD133+ cells bear
similar cardiac regeneration potential
In order to assess the cardiac regenerative potential of
manually and automatically generated CD133+ CPs, cells
were transplanted into SCID bg mice after cardiac ische-
mia/reperfusion. Cardiac performance was analyzed by
hemodynamic measurement 3 weeks after cell trans-
plantation. PV loops demonstrate significant improve-
ment of ejection fraction (EF), end-diastolic volume
(EDV) and end-systolic volume (ESV) under baseline
condition in comparison to the untreated infarction
(MIC) after manually and automatically generated
CD133+ stem cell transplantation (Fig. 4). Under stress
conditions velocity of pressure rise (dPdtmax) and ESV
were significantly improved in comparison to MIC after
transplantation of automatically enriched CD133+ cells.
Importantly, no significant differences in cardiac regen-
eration potential were obtained between manually and
automatically isolated CD133+ stem cells.
Manually and automatically isolated CD133+ cells
positively influenced cardiac remodeling
Ligation of the LAD consistently resulted in a trans-
mural MI with its typical histologic changes including




Fig. 2 Stability of the automatically generated cell product (CP) over a storage time of 2.5 h and 24 h post manufacturing process. For the first
2.5 h, CP was stored under room temperature (RT) conditions. After 2.5 h CP was stored at 2–8 °C. Samples of CP were taken at the respective
storage time and CD45+ cells/μl (a), CD133+CD34+ cells/μl (b) and viability of CD45+ cells (c) were measured by flow cytometry in accordance
with ISHAGE guidelines. All data are presented as a mean ± SEM. n = 3. *p≤ 0.05; **p ≤ 0.01; ***p≤ 0.001 vs. CP
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collagen deposition (fibrosis) and decrease of capillary
density following hypertrophy of the cardiac cells
3 weeks after infarction. The transplantation of auto-
matically isolated CD133+ stem cells led to a significant
decrease in fibrosis (versus MIC) in both RA and BZ
(Fig. 5a). Manually isolated stem cells also resulted in a
slightly but not significantly reduced collagen depos-
ition in comparison to MIC. Moreover, explanted
hearts were perfused with biotinylated tomato lectin
followed by anti-biotin staining of the heart cryosec-
tions. Decrease of capillary density was significantly re-
duced after stem cell treatment in both RA and BZ in
comparison to MIC (Fig. 5b).
Manually and automatically isolated CD133+ cells have
beneficial effects on formation of the infarction scar
Planimetry measurements showed a trend toward reduc-
tion in infarction size after transplantation of stem cells
derived by either isolation procedure compared to MIC
(Fig. 6a). Neovascularization in the infarct scar was signifi-
cantly improved after stem cell application (versus MIC)
(Fig. 6b). No significant differences were observed between
manually and automatically isolated CD133+ stem cells.
Discussion
Therapeutic benefits of transplanted CD133+ stem cells in




Fig. 3 Hematopoietic and endothelial differentiation capacity of manually and automatically isolated CD133+ stem cells. Hematopoietic colony-
forming unit (CFU-H) and colony-forming unit endothelial cells (CFU-EC) assays were performed by seeding 1 × 103 cells directly after the isolation
procedure. Hematopoietic CFUs (CFU-E, BFU-E, CFU-GEMM, CFU-GM) (a) and endothelial CFUs (adherent, non-adherent) (b) were counted after
14 days of incubation. All numbers of counted CFUs are presented in the table (c). All data are presented as a mean ± SEM. n = 3. *p≤ 0.05;
**p≤ 0.01; ***p≤ 0.001
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for years [5–9]. In 2011, our autologous BM-derived
CD133+ CP intended for the regeneration of ischemic
heart tissue was defined as a tissue-engineered product
and classified as ATMP by the EMA. For clinical trans-
lation, the manufacturing of ATMPs requires specific
standards of quality [18, 29]. The recently developed
CE-marked Prodigy allows the automatic on-site purifi-
cation of CD133+ stem cells in a GMP-qualified ambit
under reduced clean room requirements. This closed
system reduces the risk of contamination, minimizes
inter-individual variability caused by the manufacturing
personnel and therefore enables a higher standardized
product quality compared to conventional semi-
automatic isolation systems.
In this study we demonstrate that the Prodigy is a suit-
able tool for automatic manufacturing of a CD133+ CP
from human BM in compliance with EU guidelines for
GMP. The manufactured CPs were free of microbial con-
taminations and fulfilled all defined acceptance criteria
including cellularity, viability and depletion of non-target
cells. Furthermore, we could show that automatically
isolated cells bear proliferation, differentiation and regen-
eration capacities comparable to manually isolated cells.
On average 0.52 × 106 viable CD133+ cells were iso-
lated from 59 ml sternal BM automatically in 5 ml CP
using the Prodigy within approximately 4 h. Noticeably,
this number of CD133+ cells varied in a range from
0.12 × 106 to 1 × 106. One reason for this relatively wide
variety might be individual cardiovascular risk factors of
BM donors undergoing CABG surgery [30], which have
been shown to affect the percentage of BM-derived pro-
genitor cells [31–33]. Moreover, variations in BM quality
caused by dilution with peripheral blood can influence
the number of CD133+ stem cells in the CP. However,
CD133+ cell amounts varied in the range of our accept-
ance criteria considering those inter-individual fluctua-
tions. Furthermore, results demonstrated a viability of
>80% and a depletion of 99.9% of non-target cells. While
this depletion is calculated on hematopoietic nucleated
cells alone, it is important to note that thrombocytes as
well as erythrocytes were completely absent from the
CP. In 2014 the EMA defined presence of granulocytes
and erythrocytes as a significant impurity in CPs because
they influence the functionality of target progenitor cells
and affect the LVEF recovery in a negative way [34].
Therefore, it is a prerequisite to keep the amount of
a b
c d
Fig. 4 Comparison of the cardiac regeneration potential of manually and automatically isolated CD133+ stem cells. 1 × 105 CD133+ stem cells
were intramyocardially transplanted into SCID bg mice after myocardial infarction (MI). Ejection fraction (EF) (a), velocity of pressure rise (dPdtmax)
(b), end-diastolic volume (EDV) (c), and end-systolic volume (ESV) (d) were assessed by pressure-volume (PV) loop measurements 3 weeks after
cell transplantation. For control untreated infarction (MIC) and SHAM operation were used. All parameters were measured under baseline and
under stress conditions mediated by intravenous dobutamine administration (10 μg/kg/min). Data are presented as mean ± SEM. *p≤ 0.05;
**p≤ 0.01; ***p≤ 0.001 vs. MIC; ns not significant
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these cells to a minimum. In addition, flow cytometric
measurements revealed that the entire non-target cell
population is characterized by a hematopoietic pheno-
type as evident from its expression of CD45. We assume
that within this non-target population one fraction
(CD45+/CD34low/+/CD133−) represents hematopoietic
stem and progenitor cells [35]. The second non-target
fraction (CD45+/CD34−/CD133−) seems to be in a more
progressed stage of maturation as indicated by a lower
expression of the stem cell marker CD117 and a higher
expression of the maturation marker CD14 [26]. More-
over, this fraction shows the highest expression of
CD184 (CXCR4) as well as CD309 (KDR, VEGFR2) indi-
cating a possible role in stem cell homing and in the
regulation of angiogenesis, respectively [30, 36, 37].
Therefore, we suggest that the non-target cells likely rep-
resent a mixture of phenotypically and functionally dis-
tinct stem cells and progenitors. Another important
observation is the loss of approximately half of the target
CD133+ stem cells, which were transferred into NTCB.
This limitation was also observed by Stroncek et al. [38],
who suggested that large quantities of platelets can inter-
fere with the antibody-linked paramagnetic particle
binding to hematopoietic antigens. Additionally, this
might be explained by the low expression of the CD133
antigen on the surface of these cells [34]. Moreover, our
results demonstrate that the automatic manufacturing
procedure results in a significantly lower viability and fre-
quency of CD133+ cells in the CP when compared to
manual manufacturing. This can be explained by the fact
that the manual isolation protocol includes additional cen-
trifugation steps eliminating dead cells and debris, as well
as substances increasing the purity of the CP (e.g., Pancoll,
FcR blocking reagent) – however, none of these reagents
is suitable for clinical application. Therefore, the Prodigy
is currently the only available device enabling automatic
manufacturing of a high-quality CP which fulfills all ac-
ceptance criteria and is suitable for clinical translation.
The time lag before application of ATMPs caused by
the QC and release processes after their manufacturing
may pose a serious limitation for clinical use. In this
study, the CP was stored at RT directly after the isola-
tion process for 2.5 h to ensure stable cell temperature
conditions during the whole manufacturing procedure
(isolation, transport, QC, and storage time). However,
since cells typically show metabolic activity at RT, these
a
b
Fig. 5 Effects of manually and automatically isolated CD133+ stem cells on cardiac remodeling. 1 × 105 CD133+ stem cells were intramyocardially
transplanted into SCID bg mice after myocardial infarction (MI). For evaluation of histological changes, fibrotic events (a) and decrease of capillary
density (b) at infarction border zone and remote area were analyzed 3 weeks after transplantation. Animals with untreated infarction (MIC) and
SHAM operation were used as control groups. Data are presented as mean ± SEM. *p≤ 0.05; **p ≤ 0.01; ***p≤ 0.001 vs. MIC; ns not significant
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storage conditions (0.9% NaCl supplemented with autolo-
gous plasma) are not suitable for longer time periods.
Therefore, the CP was stored at 4 °C after the initial 2.5 h
in order to minimize the cell metabolism [39].
After a storage time of 24 h, there was a clear tendency
toward a decrease of the CD133+CD34+ cell numbers per
microliter. Yet, this phenomenon of reduced CD133
+CD34+ cells is due to reduced CD34 and CD133 protein
expression over time as previously described by our group
[28]. Importantly, we did not find any significant changes
in the percentage of apoptotic and necrotic cells for up to
24 h post manufacturing. This demonstrates the suitability
of the automatically generated CD133+ CP for clinical ap-
plication even 24 h post manufacturing. Our results are in
agreement with previous data of Belotti et al., where a
stable quality of CD133+ cells was reported for up to 12 h
at 2–8 °C in serum-free basal medium [31]. In 2014 our
group recommended a maximal storage time of 30 h at
2–8 °C for hematopoietic stem cells [28]. However, keep-
ing the storage time as short as possible is of course al-
ways preferable to avoid cell loss.
In order to ensure the biological activity of the automatic-
ally generated CD133+ CPs 2.5 h post manufacturing, we
applied different in vitro and in vivo assays. For evaluation,
we compared the obtained data with manually isolated
CD133+ cells, which have been used in several preclinical
[13, 30] and clinical [7, 40, 41] studies for cardiac regener-
ation and served as an experimental model, here. In vitro
differentiation assays were performed in order to investigate
the regeneration potential of CD133+ stem cells, which is
based on their secretion of paracrine factors and their direct
participation into neovascularization [14, 16]. Thereby, we
did neither detect significant differences in endothelial nor
in hematopoietic differentiation capacities between auto-
matically and manually isolated CD133+ cells. This indi-
cates that the multipotent potential of these cells is not
affected by the Prodigy manufacturing process. To confirm
therapeutic effects of CD133+ cells in vivo, heart function
was assessed in mice after induction of MI. After trans-
plantation of manually isolated CD133+ cells a significant
improvement in cardiac function was detected compared
to MIC, which is in accordance with previous findings of
our [13] and other groups [42]. Importantly, for the first
time we also could demonstrate that automatically isolated
CD133+ cells led to a significant increase in different car-
diac function parameters in vivo. Additionally, our data re-
vealed that the automatically isolated CD133+ CPs were
actively involved in the reduction of the cardiac remodeling
a
b
Fig. 6 Effects of manually and automatically isolated CD133+ stem cells on formation of infarction scar. 1 × 105 CD133+ stem cells were
intramyocardially transplanted into SCID bg mice after myocardial infarction (MI). Three weeks after cell transplantation infarction size (a) and
infiltration of the infarcted scar with new blood vessels (b) were analyzed. For control untreated infarction (MIC) and SHAM operation were used.
Data are presented as mean ± SEM. *p ≤ 0.05; **p≤ 0.01; ***p≤ 0.001 vs. MIC; ns not significant
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process and participated in neovascularization at a level
comparable to manually isolated cells.
Conclusions
Our data demonstrate that the automatic Prodigy is a
suitable system for safe and time-saving on-site manu-
facturing of a high-quality BM-derived CD133+ CP in a
GMP-qualified ambit intended for the treatment of is-
chemic heart disease. The manufacturing process was
performed in compliance with EU guidelines for GMP
and the purified CD133+ CP fulfilled all defined accept-
ance criteria, which were adapted from our currently
running phase III clinical trial PERFECT. The obtained
data were part of the GMP evaluation process by the
competent local authority, which granted the manufac-
turing license for our cell manufacturing facility. More-
over, in vitro and in vivo generated preclinical data
evidenced safety, biological activity, and cardiac regener-
ation potential of purified cells, which is a prerequisite
for the initiation of first clinical trials applying an auto-
matically generated CD133+ CP using the Prodigy.
Additional files
Additional file 1: Figure S1. Schematic representation of two different
logistical procedures used for the manufacturing of stem cell products in
cardiovascular regenerative medicine. Manual/semi-automatic systems
require centralized GMP-compliant manufacturing by an external service
provider (a). Entirely closed systems such as the automatic CliniMACS
Prodigy® enable decentralized GMP-compliant manufacturing by an
in-house facility (b). a Centralized GMP-compliant manufacturing by an
external service provider: few specialized contractors are available for a
distinct cell product because standardized high-level clean rooms (Class
A in B) and sophisticated training are required for the manual or
semi-automatic manufacturing. This results in higher costs of the therapy
due to an increased logistical effort (e.g., long-distance transportation)
and longer hospitalization of the patients as well as a possible loss of cell
product quality (e.g., CliniMACS® Plus). b Decentralized GMP-compliant
manufacturing by an in-house facility: cell products intended for clinical
application can be manufactured on-site owing to reduced clean room
requirements (Class A in D) and easier standardization of processes with
minimized inter-individual variability due to automatic manufacturing.
Lower logistical effort (in-house transport) and shorter hospitalization
enables minimized costs plus a better and stable quality of the cell
product (e.g., CliniMACS Prodigy®). (PDF 109 kb)
Additional file 2: Table S1. Overview of data obtained from
CliniMACS® Prodigy BM-133 System validation process (a) and product
quality review (PQR) (b). Volumes of samples were ascertained by visual
control (bone marrow (BM)) or by weighing (cell product (CP), non-target
cell bag (NTCB), waste bag (WB)). Total numbers of viable CD45+ and
CD133+ cells were calculated by multiplying absolute cell numbers per
volume unit with corresponding volumes. The frequencies of viable
CD133+ cells were measured by flow cytometry in accordance with ISHAGE
guidelines. (DOC 42 kb)
Additional file 3: Table S2. Overview of data obtained from manual cell
isolation. Volumes of bone marrow (BM) samples were ascertained by visual
control. Total numbers of viable CD133+ cells were determined using Neubauer
hemocytometer. The frequencies of viable CD133+ cells were measured by flow
cytometry in accordance with ISHAGE guidelines. (DOC 36 kb)
Additional file 4: Figure S2. Schematic schedule of the CD133+ cell
isolation process using the CliniMACS Prodigy® BM-133 system. Gray:
manual steps (two operators); green: semi-automatic steps (one operator,
dual control); blue: automatic steps. (PDF 1368 kb)
Additional file 5: Table S3. List of antibodies used for flow cytometry-
based quality control of manually isolated CD133+ stem cells and for the
characterization of stemness marker expression in the automatically
generated cell product. (DOC 33 kb)
Additional file 6: Figure S5. Representative ISHAGE-based gating
strategy used for the quality control of the automatically generated
cell product (CP). Debris was excluded from CD45+ cells (a). CD34+
cells were selected from viable CD45+ cells (b). Events with high
expression of the CD45 marker were excluded from viable CD45+/CD34
+cells (c). FSC/SSC backgate was employed to select viable CD45
+/CD34+ hematopoietic progenitor cells (HPCs) with blast morph-
ology (d). Viable CD45+/CD34+/CD133+ cells were selected (e).
Events with high expression of the CD45 marker were excluded
from viable CD45+/CD34+/CD133+ cells (f). FSC/SSC backgate was
employed to select viable CD45+/CD34+/CD133+ HPCs with blast
morphology (g). A control gate (‘Ly’, lymphocytes) was used during
exclusion of mature CD45+ HSCs. Red: target cell population. Gray:
dead cells. (PDF 374 kb)
Additional file 7: Figure S6. Phenotypic and morphologic
characterization of non-target cell populations presented in the automatically
generated cell product (CP). Non-target cell populations were subdivided
into three fractions: CD45+/CD34− (region J) and CD45+/CD34low (region Q)
(a); CD45+/CD34+/CD133− (region I) (b). CD45+/CD34-/low non-target cells
were further analyzed concerning their CD133 expression (regions M and R,
respectively). Size and granularity of all three fractions were evaluated: region
K and T: smaller than target cell population; region O, S and P: same size/
granularity than target cell population; region L: higher granularity than target
cell population. (PDF 130 kb)
Additional file 8: Table S4. Stemness marker expression of target and
non-target cell fractions presented in the automatically generated cell
product (CP). For phenotype characterization the expression of stemness
markers (CD117, CD184, CD309, CD14) was evaluated in target cells
(CD45+CD34+CD133+) (a) and non-target cells (CD45+CD34−CD133−,
CD45+CD34lowCD133−, CD45+CD34+CD133−) (b) using flow cytometry.
The respective analysis was made in accordance with ISHAGE guidelines.
Data are presented as a mean ± SEM, n = 9. (DOC 37 kb)
Additional file 9: Figure S7. Determination of apoptotic and necrotic
cells in the automatically generated cell product (CP) after storage. The
percentage of viable, early-stage apoptotic, late-stage apoptotic and
necrotic cells was analyzed by flow cytometric measurements using
Annexin V Apoptosis Detection Kit. Samples of CP were taken at the
respective storage time. All data are presented as a mean ± SEM. n = 3.
*p≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. (PDF 108 kb)
Additional file 10: Figure S3. Uptake of acetylated low-density lipopro-
tein (acLDL) of colony-forming unit endothelial cell (CFU-EC) assay-derived
cells. CFU-EC assay was performed and after 29 days incubation the uptake
of acLDL (green) was examined by immunostaining in non-adherent cells.
Nuclei were stained with Hoechst dye (blue). Pictures were taken using
ELYRA PS.1 LSM 780 microscope (Carl Zeiss GmbH). Images of manually (a
and b) and automatically (c and d) isolated cells. Scale bars: 100 μm (a and
c) and 20 μm (b and d). (PDF 341 kb)
Additional file 11: Figure S4. Von Willebrand factor (vWF) expression
of colony-forming unit endothelial cell (CFU-EC) assay-derived cells. CFU-
EC assay was performed and after 29 days incubation the vWF expression
(green) was examined by immunostaining in non-adherent cells. Nuclei
were stained with Hoechst dye (blue). Pictures were taken using ELYRA
PS.1 LSM 780 microscope (Carl Zeiss GmbH). Images of manually (a and
b) and automatically (c and d) isolated cells. Scale bars: 100 μm (a and c)
and 20 μm (b and d). (PDF 295 kb)
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immunodeficient; SEM: standard error of the mean; TS: tubing set; vWF: von
Willebrand factor; WB: waste bag
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